1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novartis AG

Novartis AG

NVSEF
Novartis AGUS flagOther OTC
144.14
USD
- -
- -
275.03BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.6
22.11
20.97
20.79
18.5
19.88
21.25
21.91
19.6
19.93
22.47
25.63
29.23
29.42
Basic EPS, GAAP
3.76
4.21
7.4
2.82
3.28
5.44
5.12
3.55
10.71
3.19
7.15
5.92
7.21
7.04
Free Cash Flow per Basic Share
4.01
4.33
3.49
3.61
4.4
5.01
4.96
4.86
5.58
5.5
5.64
6.84
7.86
8.3
Dividend per Share
2.5
2.81
2.76
2.72
2.77
3
2.9
3.07
3.28
3.44
3.49
3.78
4.03
4.51
Book Value per Share
30.34
30.27
33.86
34.53
33.51
35.85
26.28
25.5
32.05
29.54
24.3
23.47
0.4
19.75
Tangible Book Value per Share
6.39
7.3
4.88
5.29
5.32
2.02
0.1
-4.45
1.8
-0.7
-1.67
-3.74
-4.35
-14.61
Basic Weighted Avg Shares
2,441
2,426
2,403
2,378
2,346
2,319
2,291
2,277
2,243
2,181
2,077
2,018
1,939
1,923
Sales/Revenue/Turnover
52,716
53,634
50,387
49,436
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
56,578
Operating Margin (%)
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.43
Depreciation Expense
4,405
4,682
5,471
6,043
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
5,399
Net Income, GAAP
9,175
10,210
17,783
6,712
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
13,534
Effective Tax Rate (%)
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
14.38
Profit Margin (%)
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
23.92
Working Capital
4,174
10,588
-863
2,722
4,805
5,956
1,240
-3,386
15,510
8,254
4,091
1,012
3,182
-4,767
LT Debt
11,242
13,799
16,327
17,897
23,224
22,470
22,056
27,978
24,523
21,782
20,034
22,934
29,592
39,110
Total Equity
74,472
70,844
77,122
74,891
74,227
78,692
55,551
56,666
67,822
59,423
46,750
44,126
46,549
38,927
Return on Invested Capital (%)
10.14
10.26
7.96
7.02
6.98
7
7.25
8.97
9.42
6.96
11.05
16.64
18.61
18.42
Return on Capital (%)
17.08
11.57
18.61
7.01
7.81
12.1
12.12
9.47
24.87
7.8
18.48
16.48
25.99
18.55
Return on Common Equity (%)
24.44
13.84
22.97
8.21
9.59
15.59
16.37
13.65
36.97
10.2
25.85
24.41
58.12
34.44

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7,784
5,784
7,888
LT Borrowings
22,598
27,935
37,447
LT Finance Leases
1,640
1,657
1,663
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,919
1,908
1,908
Market Capitalization
243,105
268,134
279,845

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28,198
30,460
26,607
Cash, Cash Equivalents & STI
9,753
11,533
6,977
Accounts Receivable, Net
8,844
8,937
9,386
Inventories
6,421
6,269
6,286
Total Current Liabilities
32,000
27,278
31,374
Payables & Accruals
7,897
9,517
6,129
ST Debt
7,784
5,784
7,888
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-2.83%
5.49%
Free Cash Flow
6.52%
6.98%
10.42%
Net Income, GAAP
21.56%
47.51%
17.11%
Sales/Revenue/Turnover
1.5%
2.95%
9.57%
Total Cash Common Dividend
1.72%
2.32%
2.54%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,120
12,872
13,172
13,558
51,722
2025
13,620
14,836
14,358
13,860
56,674
2026
13,524
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.32
1.6
1.58
1.42
5.92
2025
1.83
2.07
- -
1.26
7.21
2026
1.65
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.55
1.19
- -
- -
3.78
2025
2.71
1.28
- -
- -
4.03
2026
3.25
- -
- -
- -
- -

Company Description

APIChat
CEO
Vasant Narasimhan
Full Time Employees
75,883
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lichtstrasse 35 Basel Switzerland 4056
IPO Date
Apr 26, 2010
CIK
0001114448
Website
novartis.com
Similar Companies
AbbVie Inc. (4AB.DE)
Organon & Co. (OGN)
Shandong Jintai Group Co., Ltd. (600385.SS)
Roche Holding AG (RO.SW)
Roche Holding AG (0QQ6.L)
Daiichi Sankyo Company, Limited (4568.T)
Business
Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel that focuses on the research, development, manufacturing, and marketing of innovative medicines for patients with serious diseases across oncology, immunology, neuroscience, cardiovascular, renal, metabolic, and other therapeutic areas. The company offers a broad portfolio of branded pharmaceuticals including Kisqali (ribociclib) for breast cancer; Entresto (sacubitril/valsartan) for heart failure; Cosentyx (secukinumab) for inflammatory conditions such as psoriasis; Scemblix (asciminib) and Tasigna (nilotinib) for chronic myeloid leukemia; Pluvicto for prostate cancer; Fabhalta (iptacopan) for rare kidney diseases including C3G and IgA nephropathy; Sandostatin (octreotide) and Signifor (pasireotide) for acromegaly and Cushing's disease; Gilenya (fingolimod) and Mayzent (siponimod) for multiple sclerosis; Diovan (valsartan) and Exforge (amlodipine/valsartan) for hypertension; Lucentis (ranibizumab) for eye diseases; Gleevec (imatinib) for oncology; Kymriah (tisagenlecleucel), a CAR-T cell therapy for blood cancers; and radioligand therapies, cell and gene therapies, as well as treatments for infectious diseases like malaria and influenza; it operates globally with a presence in over 100 countries, supported by R&D hubs in Basel, Cambridge, and San Diego. Formed in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis spun off its generics business Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on innovative medicines. Recent developments include the October 2025 agreement to acquire Avidity Biosciences for approximately $12 billion to enhance RNA therapeutics for neuromuscular diseases; April 2025 plans for a $23 billion US manufacturing and R&D expansion across 10 facilities including a new radioligand therapy plant in California and a $1.1 billion San Diego research hub; 2025 acquisitions of Anthos Therapeutics and Regulus Therapeutics; partnerships and licensing deals exceeding $17 billion such as with Argo Biopharma for siRNA candidates, Dren Bio for bispecific antibodies, and Ratio Therapeutics for radiotherapeutics; new approvals for Pluvicto in pre-taxane prostate cancer, Vanrafia for IgA nephropathy, and Fabhalta for C3G; and projections for 5-6% compound annual sales growth through 2029-2030 bolstered by these pipeline advancements.

Company News

APIChat

  • globenewswire.com

    New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer